Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics Inc (VVOS) provides innovative solutions for sleep-disordered breathing through its proprietary oral appliance therapy and integrated clinical protocols. This news hub offers investors and healthcare professionals direct access to official announcements, financial disclosures, and progress updates on the company's non-invasive treatment alternatives for obstructive sleep apnea.
Our curated collection features regulatory filings, partnership announcements, clinical trial updates, and technology developments. Users will find timely information about the Vivos System implementation, insurance coverage expansions, and research collaborations within the sleep medicine field.
The page organizes content by key categories including quarterly earnings reports, FDA communications, provider network growth, and peer-reviewed study publications. Each update maintains factual accuracy while highlighting the company's position in the $7 billion sleep apnea treatment market.
Bookmark this page for streamlined tracking of Vivos' progress in commercializing its oral appliance technology and expanding its licensed provider network. Check regularly for new developments in patient outcomes data and healthcare provider adoption rates across North America.
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device company focusing on sleep-related breathing disorders, has announced the release of its second quarter 2024 financial results after market close on August 14, 2024. The company will host a conference call at 5:00 pm ET on the same day to discuss the results and provide updates on recent achievements and developments.
Investors can access the call by dialing (800) 717-1738 (US) or (646) 307-1865 (international). A replay will be available until August 28, 2024, accessible by dialing (844) 512-2921 (US) or (412) 317-6671 (international) with passcode 1157721. A live webcast and 30-day archive will be available on the company's investor relations website.
Vivos Therapeutics announced positive results from a 7-month, multi-site pilot of its new provider-based marketing and distribution model. Conducted in seven dental and one ENT office, the pilot involved 99 patients with diverse demographics. 79% of newly diagnosed adult OSA patients preferred Vivos' oral appliance therapy over CPAP, with Vivos' devices chosen 5 to 1 over traditional appliances. Pediatric patients with orofacial issues were also successfully treated. Vivos aims to drive revenue through collaborations with dentists and sleep specialists, expecting positive impacts on new cases, revenue growth, and gross profit.
Vivos Therapeutics (NASDAQ: VVOS) announced a $7.5 million private equity investment from Seneca Partners to support a new strategic alliance with sleep treatment centers in Colorado. The alliance aims to enhance revenue through a new marketing and distribution model for Vivos' OSA treatment devices, starting with two centers in July 2024. Vivos intends to expand this model nationally. The investment boosts Vivos' cash reserves and shareholders' equity. Seneca will also offer management advisory services. Key investment terms include the purchase of 3,220,266 shares and associated warrants, with an 'at the market' price of $2.329 per share.
Vivos Therapeutics (NASDAQ: VVOS) reported Q1 2024 financial results, highlighting a 22% reduction in operating expenses and a gross margin of 57%. Revenue for Q1 2024 was $3.4 million, down from $3.8 million in Q1 2023, due to lower VIP enrollments and CARE appliance revenue. However, revenue from pediatric and lifeline appliances and home sleep testing services increased. Gross profit was $1.9 million. Despite revenue decline, cost-cutting initiatives reduced operating loss by 24% year-over-year. Cash and cash equivalents were $2.6 million. Over 42,600 patients have been treated with Vivos' devices, and regulatory approvals for Medicare reimbursement were obtained in April 2024. The company expects positive cash flow by end-2024, driven by new strategic revenue initiatives and improved market conditions.
Vivos Therapeutics (NASDAQ: VVOS), a key player in medical devices for sleep-related breathing disorders, will release its Q1 2024 financial results today, May 14, 2024, after market close. The company will hold a conference call at 5:00 p.m. ET to discuss financial results and recent milestones. Investors can join the call via provided phone numbers or access a live webcast on the company's website. A replay of the call will be available until May 28, 2024.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
